bristol-myers glp-1 receptor agonist products Frontiers Frontiers | Clinical perspectives on
Description
For pancreatitis, there was a 0.5% incidence of pancreatitis in people taking Ozempic, a 0.8% risk in people taking Saxenda, and a 0.01% incidence in people taking Contrave, representing a more than ninefold increase
Considering the chronic nature of diabetes-related complications (e.g., CVDs), the follow-up period of this real-world study may not be sufficient to assess the long-term benefits of GLP-1RA therapy
3 The potential CV and renal effects of linagliptin have been investigated in the CAROLINA and CARMELINA trials
Can they cause dehydration
